Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5930
+0.01803.13%
Post-market: 0.59520.0022+0.37%17:05 EDT
Volume:5.56M
Turnover:3.24M
Market Cap:144.10M
PE:-0.79
High:0.6067
Open:0.5900
Low:0.5723
Close:0.5750
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.94
T/O Rate:2.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-13.87
PE(LYR):-0.33

Loading ...

Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA

TIPRANKS
·
Oct 01

Outlook Therapeutics - on Track for U.S. Launch of Lytenava Before Year-End 2026

THOMSON REUTERS
·
Oct 01

Outlook Therapeutics Submits Hcpcs Level Ii Application to CMS for Permanent J-Code for Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Oct 01

Outlook Therapeutics Risks NASDAQ Delisting After 30-Day Sub-$1 Bid-Price Stretch

Reuters
·
Oct 01

Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences up 156%

Dow Jones
·
Sep 28

Outlook Therapeutics Wins FDA Approval for Lytenava in Wet AMD

Reuters
·
Sep 10

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

GlobeNewswire
·
Sep 10

Outlook Therapeutics CFO Kevin Michael Lundquist Files Initial Beneficial Ownership Statement

Reuters
·
Sep 03

Outlook Therapeutics Names Kevin Lundquist CFO, Replacing Lawrence Kenyon

Reuters
·
Aug 28

Outlook Therapeutics - Lawrence Kenyon to Step Down as CFO Effective September 1, 2026

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as it Prepares for U.S. Commercial Launch of Lytenava™

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Posts CEO Bob Jahr “Why Now” Investor Conference Webcast on Demand

Reuters
·
Aug 27

Outlook Therapeutics Delays Q2 Form 10-Q Filing After Finance Staff Turnover

Reuters
·
Aug 18

Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear

Simply Wall St.
·
Aug 15

Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9

Reuters
·
Aug 15

Outlook Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop

Reuters
·
Aug 14

Outlook Therapeutics Q3 EPS USD -0.15

THOMSON REUTERS
·
Aug 14

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava™

THOMSON REUTERS
·
Aug 14

Press Release: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava(tm)

Dow Jones
·
Aug 14